No Data
No Data
Express News | Axsome Therapeutics Inc : UBS Cuts Target Price to $143 From $149
Earnings Preview: Axsome Therapeutics (AXSM) Q1 Earnings Expected to Decline
Investors in Axsome Therapeutics (NASDAQ:AXSM) Have Seen Strong Returns of 235% Over the Past Three Years
Morgan Stanley Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $190
Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK), Axsome Therapeutics (AXSM) and Greenwich LifeSciences (GLSI)
Positive Outlook on Axsome Therapeutics' AXS-12 for Narcolepsy Treatment Amid Promising Phase III Results